바이오마린제약(주)
MX ˙ BMV ˙ US09061G1013
SecurityMX:BMRN / BioMarin Pharmaceutical Inc.
InstitutionVident Advisory, LLC
Latest Disclosed Ownership6,506 shares
Latest Disclosed Value $ 367,524
Vident Advisory, LLC reports 33.90% increase in ownership of BMRN / BioMarin Pharmaceutical Inc.

On May 14, 2026 - Vident Advisory, LLC filed a 13F-HR form disclosing ownership of 6,506 shares of BioMarin Pharmaceutical Inc. (MX:BMRN) valued at $367,524 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 18, 2026 disclosing 4,859 shares of BioMarin Pharmaceutical Inc.. This represents a change in shares of 33.90% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 6,506 1,647 33.90 368 27.43 0.0010
2026-02-18 2025-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 4,859 -3,844 -44.17 289 -38.85 0.0026
2025-11-14 2025-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 8,703 -180 -2.03 471 -3.48 0.0045
2025-08-14 2025-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 8,883 2,837 46.92 488 14.29 0.0055
2025-05-15 2025-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 6,046 6,046 427 0.0062
2024-11-14 2024-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 0 -2,877 -100.00 0 -100.00
2024-08-14 2024-06-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,877 160 5.89 237 -0.42 0.0065
2024-05-14 2024-03-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,717 14 0.52 237 -8.85 0.0049
2024-02-14 2023-12-31 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,703 231 9.34 261 19.27 0.0066
2024-02-21 2023-09-30 13F/A-01 BIOMARIN PHARMACEUTICAL COM 09061G101 2,472 2,472 219 0.0068
2023-11-14 2023-09-30 13F BIOMARIN PHARMACEUTICAL COM 09061G101 2,472 2,472 219 0.0055
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.